Navigation Links
InspireMD Announces Pricing of Underwritten Public Offering of Common Stock and Listing on NYSE MKT
Date:4/11/2013

4-2806.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About InspireMD, Inc.

InspireMD is a medical device company focusing on the development and commercialization of its proprietary stent system technology, MGuard™. InspireMD intends to pursue applications of this technology in coronary, carotid and peripheral artery procedures. InspireMD's common stock is quoted on the NYSE MKT under the ticker symbol NSPR.

Forward-looking Statements:

This press release contains "forward-looking statements." Such statements may be preceded by the words "intends," "may," "will," "plans," "expects," "anticipates," "projects," "predicts," "estimates," "aims," "believes," "hopes," "potential" or similar words. Forward-looking statements are not guarantees of future performance, are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company's control, and cannot be predicted or quantified and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation, risks and uncertainties associated with (i) market acceptance of our existing and new products, (ii) negative clinical trial results or lengthy product delays in key markets, (iii) an inability to secure regulatory approvals for the sale of our products, (iv) intense competition in the medical device industry from much larger, multi-national companies, (v) product liability claims, (vi) our limited manufacturing capabilities and reliance on subcontractors for assistance, (vii) insufficient or inadequate reimbursement by gove
'/>"/>

SOURCE InspireMD, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. InspireMD Announces First Quarter 2012 Financial Results
2. InspireMD Announces Positive 3-Year Results from Extended MAGICAL trial
3. InspireMD to Present at Inaugural Marcum Microcap Conference on June 20th in New York
4. InspireMD to Present at Harvard Investors Group on June 27 in New York
5. InspireMD Announces Positive Results From MGuard(TM) Stent MASTER Trial for Emergency Treatment of Heart Attack Patients
6. InspireMD Reports Results For Period Ending Sept. 30, 2012
7. Positive Results of InspireMDs MASTER Trial to be Published on November 6 in Journal of American College of Cardiology
8. InspireMD to Discuss MGuard(TM) and the MASTER Randomized Trial Results at the ICI 2012 Meeting
9. InspireMD Reports Results for Period Ended Dec. 31, 2012
10. InspireMD Files Amended Registration Statement for Proposed Public Offering of Common Stock
11. InspireMD Receives CE Mark Approval for Carotid Embolic Protection Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/22/2014)... , Sept. 22, 2014  For many ... surgery often means facing the prospect of large, ... be imagined, regular activities are also impacted, such ... the severity of the problem, some patients even ... which can even lead to permanent damage for ...
(Date:9/22/2014)... SAN FRANCISCO , Sept. 22, 2014  Sutro ... FierceBiotech as one of 2014,s Fierce 15 ... promising private biotechnology companies in the industry.  ... A-list group of backers as well as industry partners ... developing antibody-drug conjugates and bispecifics," says John Carroll ...
(Date:9/22/2014)... Sept. 22, 2014  Seres Health, a clinical-stage therapeutics ... human microbiome, today announced that it has been named ... 15 biotechnology companies, designating it as one of the ... "Amid a great deal of ain,t-it-cool science ... and commitment to practical therapeutic development," says Damian ...
Breaking Medicine Technology:Phoenix Arizona Hand Doctor Develops Revolutionary New Surgery System, Eliminates Need for Large Incisions 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 2FierceBiotech names Sutro Biopharma as one of its "Fierce 15" Biotech Companies of 2014 3Seres Health Named a "Fierce 15" Biotech Company for 2014 2
... Six-Month Data Show Bifeprunox Maintained Stability,Significantly Longer ... and,Lipid Profile Comparable with Placebo , MARIETTA, ... - Solvay,Pharmaceuticals, Inc., Wyeth Pharmaceuticals, a division ... study results on,bifeprunox, an investigational treatment for ...
... Support FDA Approval of SEROQUEL XR--, WILMINGTON, ... announced that two analyses from a large-scale,study ... (quetiapine,fumarate) Extended-Release Tablets, a once-daily medicine for ... presented today,at the annual meeting of the ...
Cached Medicine Technology:New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 2New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 3New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 4New Long-Term Data Analyses for Bifeprunox Show Favorable Effects,Versus Placebo in Stabilized Patients with Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 2New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 3New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 4New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 5New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 6New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 7New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 8New Study Analyses Confirm Once-Daily Seroquel XR Extended-Release,Tablets as Effective Treatment for Schizophrenia 9
(Date:9/22/2014)... Asians living in Canada have a higher rate of ... with while people, McMaster researchers have found. , ... Medical Association Journal (CMAJ Open) and may be ... fastest-growing ethnic groups in the country is the more ... comprising about three percent of the population. They include ...
(Date:9/22/2014)... researchers have published a pilot study showing the ... people with multiple sclerosis (MS). Improvements were ... and pain. "Development and effectiveness of a ... Description and outcomes" was epublished ahead of print ... of MS Care (doi: 10.7224/1537-2073.2013-045). The authors ...
(Date:9/22/2014)... -- Two new prescription devices approved by the U.S. ... for people with migraine headaches who don,t tolerate migraine ... device -- the Cefaly -- is designed to prevent ... is meant to be used when migraines first start, ... been looking for alternative migraine treatments. Because these devices ...
(Date:9/22/2014)... Severe weather can occur with little warning, so it’s ... of National Preparedness Month, Amica Insurance is offering the ... unexpected:, , Build an emergency supply kit. It ... gallon of water per person per day for at least 72 ... includes pets so your family knows what to do and where ...
(Date:9/22/2014)... September 22, 2014 The New York ... of Surgery at the Icahn School of Medicine at ... York Group for Plastic Surgery gives residents of New ... a team of world-renowned plastic surgeons performing innovative reconstructive ... Salzberg, MD, who led NYGPS, was named the Director ...
Breaking Medicine News(10 mins):Health News:Higher risk of heart disease for South Asians in Canada 2Health News:Noninvasive Devices May Help Migraines, FDA Says 2Health News:Amica Shares Tips for National Preparedness Month 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 2Health News:The New York Group for Plastic Surgery Joins Mount Sinai Doctors 3
... San Diego, CA, August 18, 2009 While video gaming ... adults, research shows that the average age of players in ... Disease Control and Prevention (CDC), Emory University and Andrews University ... from 19 to 90 in the Seattle-Tacoma area on health ...
... INDIANAPOLIS, Aug. 17 Eli Lilly and Company (NYSE: ... for the Eastern District of Michigan has granted a motion by ... ,826 patent, or method-of-use patent, for Gemzar((R)) (gemcitabine HCl for injection) ... no bearing on Gemzar,s compound patent, which remains valid until November ...
... , , MIAMI, Aug. 17 In the ... Make You Thin , writer John Cloud tells us that these days, the ... wasting their time. He says that "exercise, in other words, isn,t necessarily helping ... After reading this article, Marta Montenegro is on a ...
... , WASHINGTON, Aug. 17 Earlier this ... Abbey College, a Roman-Catholic institution, must provide insurance coverage for ... http://www.newscom.com/cgi-bin/prnh/20080930/FRCLOGO ) , , The ruling goes ... state law which provides for exemption to for religious entities. ...
... A new study shows that elderly patients who ... ulcer bleeding had a two-day shorter hospital stay and ... patients who did not receive endoscopy within the first ... Center in Cleveland, Ohio, note that unless specific contraindications ...
... benign, others might pose dangers, experts say , MONDAY, ... skin can "trap" large amounts of indoor ozone, then "spit" ... the skin and the lungs, new research suggests. , "They ... ozone and cause more irritation to the skin," explained one ...
Cached Medicine News:Health News:New study finds links between video-game playing and health risks in adults 2Health News:New study finds links between video-game playing and health risks in adults 3Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 2Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 3Health News:U.S. District Court Rules Against Lilly Regarding Gemzar Patent 4Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 2Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 3Health News:Editor-In-Chief of SOBeFiT Magazine, Marta Montenegro, Says Time Magazine's Article 'Why Exercise Won't Make You Thin' Sends the Wrong Message 4Health News:Family Research Council President Tony Perkins Asks: Is This What President Obama Means by 'Robust' Conscience Protections? 2Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 2Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 3Health News:Endoscopy within 24 hours shows better outcomes in elderly with peptic ulcer bleeding 4Health News:Toxins May Form When Skin, Indoor Ozone Meet 2Health News:Toxins May Form When Skin, Indoor Ozone Meet 3
Mounted on an extremely lightweight,and flexible cotton headband, the,Trueview Sport adjusts around the head,and the crown strap for a comfortable,and secure fit,...
The Convertible lets you attach the,High Lite optic directly to your loupes....
Mounted on a remarkably lightweight and,flexible cotton headband with crown strap,the Sport is fully adjustable....
... content (93% by volume) of any DBM ... handling characteristics, which will enhance any graft ... or as a graft extender for larger ... high molecular weight biocompatible carrier allows DBX ...
Medicine Products: